Heart Failure Medication Withdrawal in Patients With Improved Cardiac Function After Atrial Fibrillation - Takeaways - MDSpire

Heart Failure Medication Withdrawal in Patients With Improved Cardiac Function After Atrial Fibrillation

  • By

  • Sitong Li

  • Yidan Sun

  • Yiwei Lai

  • Hui Wang

  • Jiancheng Han

  • Yuge Zhang

  • Mingyang Gao

  • Jue Wang

  • Jingrui Zhang

  • Liu He

  • Jing Cui

  • Xueyuan Guo

  • Song Zuo

  • Xiaoxia Liu

  • Nian Liu

  • Songnan Li

  • Ning Zhou

  • Ribo Tang

  • Deyong Long

  • Caihua Sang

  • Xin Du

  • Jianzeng Dong

  • Changsheng Ma

  • June 26, 2026

  • 0 min

Share

  • 1

    Atrial fibrillation and heart failure often coexist, worsening outcomes through mechanisms like tachycardia and impaired atrial systole.

  • 2

    Catheter ablation improves left ventricular ejection fraction more effectively than rate control in patients with atrial fibrillation.

  • 3

    The study evaluates the feasibility and safety of phased withdrawal of guideline-directed medical therapy in patients with improved cardiac function.

  • 4

    Inclusion criteria for the trial included patients aged 18 to 80 with improved ejection fraction after catheter ablation.

  • 5

    The primary endpoint was heart failure deterioration within 6 months, assessed by changes in ejection fraction and NT-proBNP levels.

Original Source(s)

Heart Failure Medication Withdrawal in Patients With Improved Cardiac Function After Atrial Fibrillation

  • by Sitong Li, Yidan Sun, Yiwei Lai, Hui Wang, Jiancheng Han, Yuge Zhang, Mingyang Gao, Jue Wang, Jingrui Zhang, Liu He, Jing Cui, Xueyuan Guo, Song Zuo, Xiaoxia Liu, Nian Liu, Songnan Li, Ning Zhou, Ribo Tang, Deyong Long, Caihua Sang, Xin Du, Jianzeng Dong, Changsheng Ma

  • June 26, 2026

Related Content

Interaction between depressive symptoms and social support on frailty risk among patients with chronic heart failure

Epicardial adipose tissue in cardiovascular diseases: a potential therapeutic target

Cell Aging May Predict Future Disease

Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer,  and mortality across three large cohorts.